Nikhila Gandrakota
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Nikhila Gandrakota has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Manju Ramakrishnan
Rollins School of Public Health: Emory University Rollins School of Public Health
4 shared publications - Megha K. Shah
Department of Family and Preventive Medicine, Emory University School of Medicine, 100 Woodruff Circle, Atlanta, GA, 30306, United States, 1 1-404-727-4018
4 shared publications Kavya Sudireddy
UMass Chan Medical School TH Chan School of Medicine: University of Massachusetts
3 shared publications- Miranda A. Moore
Department of Medicine, Emory University, Atlanta, GA, United States
3 shared publications - Mirza Mehmood Ali Baig
Internal Medicine, Dow University of Health and Sciences, Karachi, Pakistan
3 shared publications - Naga Vijaya Lakshmi Divya Boorle
Department of Family Medicine and Public Health Sciences, Wayne State University School of Medicine, Detroit, USA
3 shared publications
Latest Publications
- Open Access
- 27 March 2026
- Published by Cambridge University Press (CUP) in Primary Health Care Research & Development
- Vol. 27, e42
Factors affecting cost-related medication non-adherence among US population with cardiovascular risk factors
Introduction: In the US, cardiovascular diseases (CVD) are the leading cause of death and disability. Cost-related medication non-adherence (CRMN) can have serious consequences and worsen CVD outcomes. We examined the relationship between CVD risk factors and CRMN among US adults. Methods: CDC’s 2019–2021 National Health Interview Survey (NHIS) data were used to examine CRMN among adults, categorized into three groups based on reported risk factors. We used chi-square tests, and logistic regression to determine factors associated with CRMN. Results: Among 49,464 participants, young, unmarried individuals, females, less educated, and participants from the South had higher CRMN than older, married individuals, males, and those with higher education residing in the other regions. Current smokers and those with more CVD risk factors also reported higher CRMN than former and never-smokers. Conversely, those aged 65 or older, with high-income, and excellent self-rated health had lower CRMN than younger participants, low-income families, and those with poor self-rated health. Public insurance and Medicaid participants had lower CRMN than uninsured (OR 0.13, 95% CI, 0.04–0.45, and OR 0.24, 95% CI, 0.15–0.36). Stratified analysis by diabetes, hypertension, and hyperlipidemia, revealed participants with high-income had lower odds of CRMN (OR 0.38, 95% CI, 0.28–0.50; OR 0.39, 95% CI, 0.28–0.58; OR 0.37, 95% CI, 0.27–0.51 respectively) than those with lower- incomes. Conclusion: Adults under 65 with more CVD risk factors and lacking insurance coverage are at higher risk of CRMN. Therefore, strengthening prescription drug coverage and targeted interventions are necessary to reduce CRMN among those with cardiovascular risk factors.
- 27 March 2026
- Published by Cambridge University Press (CUP) in Primary Health Care Research & Development
- Vol. 27, e42
Open AccessFactors affecting cost-related medication non-adherence among US population with cardiovascular risk factors
Introduction: In the US, cardiovascular diseases (CVD) are the leading cause of death and disability. Cost-related medication non-adherence (CRMN) can have serious consequences and worsen CVD outcomes. We examined the relationship between CVD risk factors and CRMN among US adults. Methods: CDC’s 2019–2021 National Health Interview Survey (NHIS) data were used to examine CRMN among adults, categorized into three groups based on reported risk factors. We used chi-square tests, and logistic regression to determine factors associated with CRMN. Results: Among 49,464 participants, young, unmarried individuals, females, less educated, and participants from the South had higher CRMN than older, married individuals, males, and those with higher education residing in the other regions. Current smokers and those with more CVD risk factors also reported higher CRMN than former and never-smokers. Conversely, those aged 65 or older, with high-income, and excellent self-rated health had lower CRMN than younger participants, low-income families, and those with poor self-rated health. Public insurance and Medicaid participants had lower CRMN than uninsured (OR 0.13, 95% CI, 0.04–0.45, and OR 0.24, 95% CI, 0.15–0.36). Stratified analysis by diabetes, hypertension, and hyperlipidemia, revealed participants with high-income had lower odds of CRMN (OR 0.38, 95% CI, 0.28–0.50; OR 0.39, 95% CI, 0.28–0.58; OR 0.37, 95% CI, 0.27–0.51 respectively) than those with lower- incomes. Conclusion: Adults under 65 with more CVD risk factors and lacking insurance coverage are at higher risk of CRMN. Therefore, strengthening prescription drug coverage and targeted interventions are necessary to reduce CRMN among those with cardiovascular risk factors.
- Open Access
- 23 September 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (18) , 5646
The Influence of Obstructive Sleep Apnea on Post-Stroke Complications: A Systematic Review and Meta-Analysis
Objectives: Evidence shows that obstructive sleep apnea (OSA) is associated with the development of stroke. This study investigates the relationship between OSA and post-stroke complications, addressing the limited data on how OSA influences the severity and development of these complications through a systematic review of existing literature. Methods: Data was collected from PubMed, Web of Science, and Scopus databases up to December 2023. Studies meeting the inclusion criteria were selected, and statistical analyses were performed using Review Manager 5.4.1. A random-effects model was used for pooling data with heterogeneity, and findings were presented using standard ratios with 95% confidence intervals. Results: The analysis included nine studies. Stroke patients with OSA did not show a significantly higher risk of post-stroke complications, which include mild cognitive impairment, dementia, insomnia, fatigue, reduced sleep quality, depression, anxiety, recurrent strokes, and death, compared with those without OSA (RR = 1.05, 95% CI 0.97 to 1.13). However, patients with high stroke severity and OSA had a slightly higher risk of post-stroke complications (RR = 1.06, 95% CI 1.01 to 1.12). Conclusions: This systematic review and meta-analysis suggests that OSA confers a higher risk of post-stroke complications in patients with high stroke severity. Further studies are required to explore the impact of OSA on post-stroke complications.
- 23 September 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (18) , 5646
Open AccessThe Influence of Obstructive Sleep Apnea on Post-Stroke Complications: A Systematic Review and Meta-Analysis
Objectives: Evidence shows that obstructive sleep apnea (OSA) is associated with the development of stroke. This study investigates the relationship between OSA and post-stroke complications, addressing the limited data on how OSA influences the severity and development of these complications through a systematic review of existing literature. Methods: Data was collected from PubMed, Web of Science, and Scopus databases up to December 2023. Studies meeting the inclusion criteria were selected, and statistical analyses were performed using Review Manager 5.4.1. A random-effects model was used for pooling data with heterogeneity, and findings were presented using standard ratios with 95% confidence intervals. Results: The analysis included nine studies. Stroke patients with OSA did not show a significantly higher risk of post-stroke complications, which include mild cognitive impairment, dementia, insomnia, fatigue, reduced sleep quality, depression, anxiety, recurrent strokes, and death, compared with those without OSA (RR = 1.05, 95% CI 0.97 to 1.13). However, patients with high stroke severity and OSA had a slightly higher risk of post-stroke complications (RR = 1.06, 95% CI 1.01 to 1.12). Conclusions: This systematic review and meta-analysis suggests that OSA confers a higher risk of post-stroke complications in patients with high stroke severity. Further studies are required to explore the impact of OSA on post-stroke complications.
- Open Access
Factors affecting Cost-Related Medication Non-Adherence among US population with Cardiovascular Risk Factors
Introduction In the US, cardiovascular diseases (CVD) are the leading cause of death and disability. Cost-related non-adherence (CRMN) can have serious consequences and worsen CVD outcomes. We examined the relationship between CVD risk factors and CRMN among US adults. Methods CDC’s 2019-2021 National Health Interview Survey (NHIS) data was used to examine CRMN among adults, categorized into three groups based on reported risk factors. We used chi-square tests, logistic regression to determine factors associated with CRMN. Results Among 49,464 participants, young, unmarried individuals, females, less educated, and participants from South had higher CRMN than older, married individuals, males, and those with higher education residing in the other regions. Current smokers and those with more CVD risk factors also had a higher CRMN than former smokers and never-smokers. Conversely, those aged 65 or older, with high-income, and excellent self-rated health had lower CRMN than younger participants, low-income families, and those with poor self-health. Public insurance and Medicaid participants had lower CRMN than uninsured (OR 0.13, 95% CI, 0.04-0.45, and OR 0.24, 95% CI, 0.15-0.36). Stratified regression analysis by disease status, i.e., diabetes, hypertension, and hyperlipidemia, revealed participants with high-income had lower odds of CRMN (OR 0.38, 95% CI 0.28-0.50; OR 0.39, 95% CI, 0.28-0.58; OR 0.37, 95% CI 0.27-0.51 respectively) than those with lower incomes. Conclusion Adults under 65 with more CVD risk factors are at higher risk of CRMN. Hence, robust prescription drug coverage and targeted interventions are necessary to lower CRMN in those with CVD risk factors.
Open AccessFactors affecting Cost-Related Medication Non-Adherence among US population with Cardiovascular Risk Factors
Introduction In the US, cardiovascular diseases (CVD) are the leading cause of death and disability. Cost-related non-adherence (CRMN) can have serious consequences and worsen CVD outcomes. We examined the relationship between CVD risk factors and CRMN among US adults. Methods CDC’s 2019-2021 National Health Interview Survey (NHIS) data was used to examine CRMN among adults, categorized into three groups based on reported risk factors. We used chi-square tests, logistic regression to determine factors associated with CRMN. Results Among 49,464 participants, young, unmarried individuals, females, less educated, and participants from South had higher CRMN than older, married individuals, males, and those with higher education residing in the other regions. Current smokers and those with more CVD risk factors also had a higher CRMN than former smokers and never-smokers. Conversely, those aged 65 or older, with high-income, and excellent self-rated health had lower CRMN than younger participants, low-income families, and those with poor self-health. Public insurance and Medicaid participants had lower CRMN than uninsured (OR 0.13, 95% CI, 0.04-0.45, and OR 0.24, 95% CI, 0.15-0.36). Stratified regression analysis by disease status, i.e., diabetes, hypertension, and hyperlipidemia, revealed participants with high-income had lower odds of CRMN (OR 0.38, 95% CI 0.28-0.50; OR 0.39, 95% CI, 0.28-0.58; OR 0.37, 95% CI 0.27-0.51 respectively) than those with lower incomes. Conclusion Adults under 65 with more CVD risk factors are at higher risk of CRMN. Hence, robust prescription drug coverage and targeted interventions are necessary to lower CRMN in those with CVD risk factors.
- Open Access
- 27 September 2023
- Published by Springer Nature in Research Square
Neurological Manifestations of Long COVID: A Systematic Review
Background Severe acute respiratory syndrome coronavirus-2 has been one of the most widespread and devastating global pandemics affecting more than 500 million people worldwide. After the cessation of active infection, the disease continues to have a disabling impact due to the persistence of fatigue, brain fog, anxiety, and depression, among the most common symptoms. This study explores the progression of neurological, neurocognitive, and neuropsychiatric symptoms over a period of 12 months or more following an initial diagnosis of COVID-19. Methods Through an electronic search of eligible studies from PubMed, Cochrane Trial register, and Google Scholar, a total of 10 studies that met the inclusion criteria were used for qualitative analysis. The systematic review highlights the similarities and differences in findings across the included studies. Results Olfactory dysfunction was prevalent in 0.9–51% of individuals, and taste impairment was observed in 1.1–21.3% of individuals. At 12 months, anxiety was more prevalent (3.5–29%) than depression (3.5–26%). Fatigue was the predominant neurocognitive complaint in 56% of individuals with severe COVID-19. Sleep difficulties were reported in 3.8–50% of individuals. Memory impairment followed by headaches and dizziness were also among the neurocognitive symptoms reported at 12 months. Conclusions From our study, we found that there is a significant neurological burden one year following the diagnosis of COVID-19. Further studies exploring the pathological mechanisms of neurological long COVID-19 are necessary to delineate better the mechanisms behind several long-term Neurological manifestations of COVID-19.
- 27 September 2023
- Published by Springer Nature in Research Square
Open AccessNeurological Manifestations of Long COVID: A Systematic Review
Background Severe acute respiratory syndrome coronavirus-2 has been one of the most widespread and devastating global pandemics affecting more than 500 million people worldwide. After the cessation of active infection, the disease continues to have a disabling impact due to the persistence of fatigue, brain fog, anxiety, and depression, among the most common symptoms. This study explores the progression of neurological, neurocognitive, and neuropsychiatric symptoms over a period of 12 months or more following an initial diagnosis of COVID-19. Methods Through an electronic search of eligible studies from PubMed, Cochrane Trial register, and Google Scholar, a total of 10 studies that met the inclusion criteria were used for qualitative analysis. The systematic review highlights the similarities and differences in findings across the included studies. Results Olfactory dysfunction was prevalent in 0.9–51% of individuals, and taste impairment was observed in 1.1–21.3% of individuals. At 12 months, anxiety was more prevalent (3.5–29%) than depression (3.5–26%). Fatigue was the predominant neurocognitive complaint in 56% of individuals with severe COVID-19. Sleep difficulties were reported in 3.8–50% of individuals. Memory impairment followed by headaches and dizziness were also among the neurocognitive symptoms reported at 12 months. Conclusions From our study, we found that there is a significant neurological burden one year following the diagnosis of COVID-19. Further studies exploring the pathological mechanisms of neurological long COVID-19 are necessary to delineate better the mechanisms behind several long-term Neurological manifestations of COVID-19.
- Open Access
- 12 September 2023
- Published by Elsevier in Brain Disorders
- Vol. 11
Vitamin D deficiency and post-stroke depression: A systematic review and meta-analysis
- 12 September 2023
- Published by Elsevier in Brain Disorders
- Vol. 11
Open AccessVitamin D deficiency and post-stroke depression: A systematic review and meta-analysis
- 2 July 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (7) , e28906
Mpox infection in an AIDS patient with syphilis manifesting with scrotal and penile cellulitis
- 2 July 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (7) , e28906
Mpox infection in an AIDS patient with syphilis manifesting with scrotal and penile cellulitis
- Open Access
- 23 February 2023
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 7 (1) , e36023
Clinical Outcomes After Use of Inhaled Corticosteroids or Oral Steroids in a COVID-19 Telemedicine Clinic Cohort: Retrospective Chart Review
Background: COVID-19 concerns remain among health care providers, as there are few outpatient treatment options. In the early days of the pandemic, treatment options for nonhospitalized patients were limited, and symptomatic treatment and home-grown guidelines that used recommendations from the Global Initiative for Asthma Management and Treatment were used. Objective: The possibility that inhaled corticosteroids (ICS) might reduce the risk of respiratory symptoms and promote recovery was the impetus for this review, as it has already been shown that in the nonhospitalized patient population, oral corticosteroids (OCS) in the acute phase could have an adverse effect on recovery. We investigated if (1) patients treated with ICS were less likely to require referral to a post–COVID-19 clinic or pulmonary specialist than patients without ICS treatment or with OCS therapy, and (2) if OCS use was associated with worse health outcomes. Methods: In a retrospective chart review, we identified all patients with acute illness due to COVID-19 that were followed and managed by a telemedicine clinic team between June and December 2020. The data were electronically pulled from electronic medical records through April 2021 and reviewed to determine which patients eventually required referral to a post–COVID-19 clinic or pulmonary specialist due to persistent respiratory symptoms of COVID-19. The data were then analyzed to compare outcomes between patients prescribed OCS and those prescribed ICS. We specifically looked at patients treated acutely with ICS or OCS that then required referral to a pulmonary specialist or post–COVID-19 clinic. We excluded any patients with a history of chronic OCS or ICS use for any reason. Results: Prescribing ICS during the acute phase did not reduce the possibility of developing persistent symptoms. There was no difference in the referral rate to a pulmonary specialist or post–COVID-19 clinic between patients treated with OCS versus ICS. However, our data may not be generalizable to other populations, as it represents a patient population enrolled in a telemedicine program at a single center. Conclusions: We found that ICS, as compared to OCS, did not reduce the risk of developing persistent respiratory symptoms. This finding adds to the body of knowledge that ICS and OCS medications remain potent treatments in patients with acute and postacute COVID-19 seen in an outpatient setting.
- 23 February 2023
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 7 (1) , e36023
Open AccessClinical Outcomes After Use of Inhaled Corticosteroids or Oral Steroids in a COVID-19 Telemedicine Clinic Cohort: Retrospective Chart Review
Background: COVID-19 concerns remain among health care providers, as there are few outpatient treatment options. In the early days of the pandemic, treatment options for nonhospitalized patients were limited, and symptomatic treatment and home-grown guidelines that used recommendations from the Global Initiative for Asthma Management and Treatment were used. Objective: The possibility that inhaled corticosteroids (ICS) might reduce the risk of respiratory symptoms and promote recovery was the impetus for this review, as it has already been shown that in the nonhospitalized patient population, oral corticosteroids (OCS) in the acute phase could have an adverse effect on recovery. We investigated if (1) patients treated with ICS were less likely to require referral to a post–COVID-19 clinic or pulmonary specialist than patients without ICS treatment or with OCS therapy, and (2) if OCS use was associated with worse health outcomes. Methods: In a retrospective chart review, we identified all patients with acute illness due to COVID-19 that were followed and managed by a telemedicine clinic team between June and December 2020. The data were electronically pulled from electronic medical records through April 2021 and reviewed to determine which patients eventually required referral to a post–COVID-19 clinic or pulmonary specialist due to persistent respiratory symptoms of COVID-19. The data were then analyzed to compare outcomes between patients prescribed OCS and those prescribed ICS. We specifically looked at patients treated acutely with ICS or OCS that then required referral to a pulmonary specialist or post–COVID-19 clinic. We excluded any patients with a history of chronic OCS or ICS use for any reason. Results: Prescribing ICS during the acute phase did not reduce the possibility of developing persistent symptoms. There was no difference in the referral rate to a pulmonary specialist or post–COVID-19 clinic between patients treated with OCS versus ICS. However, our data may not be generalizable to other populations, as it represents a patient population enrolled in a telemedicine program at a single center. Conclusions: We found that ICS, as compared to OCS, did not reduce the risk of developing persistent respiratory symptoms. This finding adds to the body of knowledge that ICS and OCS medications remain potent treatments in patients with acute and postacute COVID-19 seen in an outpatient setting.
- Open Access
- 18 January 2023
- Published by Wiley
Monkeypox infection in an AIDS patient with Syphilis manifesting with scrotal and penile cellulitis
Monkeypox infections in the US and across the world have been rising in the past few months. Most of these infections have been found to be transmitted among men who have sex with men (MSM). Our case report discusses the rare presentation of a patient with monkeypox along with multiple comorbidities, including AIDS, late latent syphilis, acute hepatitis C, and asymptomatic and scrotal and penile cellulitis secondary to MRSA. Further, our case report raises discussion on the need for further research to identify the effect of monkeypox vaccine on symptomatic patients who are immunocompromised.
- 18 January 2023
- Published by Wiley
Open AccessMonkeypox infection in an AIDS patient with Syphilis manifesting with scrotal and penile cellulitis
Monkeypox infections in the US and across the world have been rising in the past few months. Most of these infections have been found to be transmitted among men who have sex with men (MSM). Our case report discusses the rare presentation of a patient with monkeypox along with multiple comorbidities, including AIDS, late latent syphilis, acute hepatitis C, and asymptomatic and scrotal and penile cellulitis secondary to MRSA. Further, our case report raises discussion on the need for further research to identify the effect of monkeypox vaccine on symptomatic patients who are immunocompromised.
- 17 September 2022
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 50, 102454
Monkeypox coinfection with Neurosyphilis in a transgender with HIV in Atlanta, USA
- 17 September 2022
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 50, 102454
Monkeypox coinfection with Neurosyphilis in a transgender with HIV in Atlanta, USA
- Open Access
- 20 June 2022
- Published by Springer Nature in Cureus
- Vol. 14 (6) , e26121
Prevalence of Gallstones in Ulcerative Colitis and Crohn’s Disease: A Systematic Review and Meta-Analysis
The meta-analysis aimed to investigate the prevalence of gallstones (GS) in Inflammatory bowel disease (IBD), especially ulcerative colitis (UC). A systematic and thorough search was conducted on online electronic databases (PubMed/Medline, Cochrane Library, and Google Scholar) from the databases' inception to April 30th, 2022. Review Manager 5.4.1 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen) was used for all statistical analyses and forest plots. Only studies that met inclusion criteria were selected. The selected studies were pooled using a random-effect model and the results were reported in the odds ratio (OR) with their corresponding 95% confidence interval (CI). Ten studies met the final inclusion criteria and were analyzed. Patients with UC had significantly higher prevalence of GS than those in the control group (OR=1.67 [1.32-2.11]; p < 0.0001; I2=58%). There was also significant prevalence of GS in Crohn’s disease (CD) than those in control group (OR=2.22 [1.82, 2.69]; p < 0.00001; I2=31%). Analysis also showed the prevalence of GS in studies conducted in Asia (OR=2.00 [1.48, 2.70]; p < 0.00001; I2=80%) and Europe (OR= 1.84 [1.32, 2.55]; p = 0.0003; I2=45%) compared to the control group. This study provided a conclusive answer to whether GS is significant in UC or not. Our meta-analysis provides a well-powered estimate that there is a prevalence of GS in UC. CD is also significantly associated with GS.
- 20 June 2022
- Published by Springer Nature in Cureus
- Vol. 14 (6) , e26121
Open AccessPrevalence of Gallstones in Ulcerative Colitis and Crohn’s Disease: A Systematic Review and Meta-Analysis
The meta-analysis aimed to investigate the prevalence of gallstones (GS) in Inflammatory bowel disease (IBD), especially ulcerative colitis (UC). A systematic and thorough search was conducted on online electronic databases (PubMed/Medline, Cochrane Library, and Google Scholar) from the databases' inception to April 30th, 2022. Review Manager 5.4.1 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen) was used for all statistical analyses and forest plots. Only studies that met inclusion criteria were selected. The selected studies were pooled using a random-effect model and the results were reported in the odds ratio (OR) with their corresponding 95% confidence interval (CI). Ten studies met the final inclusion criteria and were analyzed. Patients with UC had significantly higher prevalence of GS than those in the control group (OR=1.67 [1.32-2.11]; p < 0.0001; I2=58%). There was also significant prevalence of GS in Crohn’s disease (CD) than those in control group (OR=2.22 [1.82, 2.69]; p < 0.00001; I2=31%). Analysis also showed the prevalence of GS in studies conducted in Asia (OR=2.00 [1.48, 2.70]; p < 0.00001; I2=80%) and Europe (OR= 1.84 [1.32, 2.55]; p = 0.0003; I2=45%) compared to the control group. This study provided a conclusive answer to whether GS is significant in UC or not. Our meta-analysis provides a well-powered estimate that there is a prevalence of GS in UC. CD is also significantly associated with GS.